Clinical Challenge: An Underdiagnosed Cause of Resistant Hypertension
Once thought to be rare, the prevalence of primary aldosteronism is estimated to be 5% to 17%, although the condition remains underdiagnosed.
Hypertension
ACE Inhibitors vs ARBs for First-Line Hypertension Treatment
Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.
HOPE-3 Trial: Lasting Effect of Rosuvastatin Prevents Major Cardiovascular Events
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Benefits of ACEIs and ARBs Outweigh Risks in Most Patients With COVID-19
The researchers conducted a comprehensive systematic review and meta-analysis comparing mortality and severe adverse events associated with receipt vs nonreceipt of ACEIs or ARBs among patients with COVID-19.
Medical and Surgical Management of Aldosteronism
The authors explore the etiology and clinical presentation of primary and secondary aldosteronism as well as medical and surgical treatment options.
FDA Identifies Most Needed Meds to Address Urgent Medical Conditions
This action was in response to an executive order issued on August 6, 2020 aimed at protecting the public against outbreaks of emerging diseases and chemical, biological, radiological, and nuclear threats.
Flavan-3-ol Intake Appears to Lower Systolic Blood Pressure
Reduction comparable to adherence to Mediterranean diet or moderate reduction in salt
Surgeon General Issues Call to Action for Hypertension Control
Three specific goals can drive change in hypertension control in the United States
Real-World Antihypertensive Prescribing Deviates From Guidelines, Study Says
The aim of the study was to analyze antihypertensive utilization patterns among patients with uncontrolled hypertension despite receiving therapy.
Bariatric Surgery Reduces Need for Antihypertensive Medications at 3 Years
Patients who undergo RYGB are less likely to need antihypertensive medications at 3 years compared with those who manage their blood pressure with medical therapy alone.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...